Enanta Pharmaceuticals (ENTA) Cash & Current Investments (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Cash & Current Investments data on file, last reported at $163.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 15.31% year-over-year to $163.8 million; the trailing twelve-month figure through Mar 2026 stood at $163.8 million (down 15.31% YoY), and the FY2025 full-year result was $188.9 million, down 23.9% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $163.8 million, down from $185.8 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $386.6 million in Q2 2023 and bottomed at $85.4 million in Q3 2023.
• The 5-year median for Cash & Current Investments is $216.7 million (2024), against an average of $232.2 million.
• The widest annual swing landed in 2023, when Cash & Current Investments tumbled 65.74%; it then surged 190.66% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $214.5 million in 2022, then jumped by 57.2% to $337.2 million in 2023, then plunged by 35.73% to $216.7 million in 2024, then dropped by 14.23% to $185.8 million in 2025, then retreated by 11.88% to $163.8 million in 2026.
• The last three Cash & Current Investments figures came in at $163.8 million (Q1 2026), $185.8 million (Q4 2025), and $188.9 million (Q3 2025), per Business Quant data.

Peer Comparison